ReviewFrontiers in pharmacology2025
Aloe-emodin: from pharmacological mechanisms to clinical applications and future perspectives.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Cardioprotective Effects ofLife (Basel, Switzerland) · 2026Review
- Mechanisms of Rhubarb-Peach Kernel in treating gastric cancer: A network pharmacology and molecular docking study.Medicine · 2026Article
- Anthraquinone-Loaded Liposomes for TAM Reprogramming in Triple-Negative Breast Cancer: Mechanistic Rationale, Delivery Logic, and Translational Challenges.Pharmaceutics · 2026Review
- Novel Aloe-Emodin Derivatives as Potential Anticancer Agents: Synthesis, Characterization and Cytotoxic Activity.Molecules (Basel, Switzerland) · 2026Article
- Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- Therapeutic effect of sustained release of aloe emodin via novel grafted polymer in electrospun nanofiber membranes on peritendinous adhesions.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products continue to be fundamental to contemporary drug discovery. Aloe-emodin, a natural anthraquinone molecule sourced from plants including aloe and rhubarb, has attracted considerable interest owing to its diverse pharmacological properties. This review analyzes the complex modes of action of AE, emphasizing its significant anti-cancer effects by targeting critical signaling pathways like PI3K/Akt, MAPK, and NF-κB, which induce apoptosis and cell cycle arrest, regulate autophagy, and inhibit metastasis. In addition to oncology, AE exhibits potent anti-inflammatory, neuroprotective, and antiviral effects primarily by reducing oxidative stress and regulating inflammatory responses. Notwithstanding its encouraging preclinical performance, the practical application of AE has been impeded by considerable obstacles, notably its inadequate bioavailability, possible toxicity, and absence of target selectivity. We rigorously assess these challenges and examine novel tactics designed to improve its therapeutic index, including nanotechnology-based drug delivery devices and alterations to chemical structures. This review seeks to reconcile the intricate pharmacology with clinical applicability, offering a prospective outlook on the use of AE as a next-generation therapeutic agent for cancer and other complex disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.